<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>UNLABELLED: BACKGROUND AND PURPOSE : The antithrombotic management of <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> (AF) is currently based on clinical scores (CHADS(2) or CHA(2)DS(2)VASc) </plain></SENT>
<SENT sid="1" pm="."><plain>The prevalence of left atrium (LA) <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> in effectively anticoagulated AF patients has been reported as being up to 7.7 % </plain></SENT>
<SENT sid="2" pm="."><plain>We tried to correlate LA/LA appendage (LAA) <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> detection with possible clinical predictors in <z:chebi fb="8" ids="10033">warfarin</z:chebi>-treated patients </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We performed trans-esophageal echocardiography on 430 patients (mean age, 60.3 ± 9.8 years) receiving oral <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> (OAC) therapy and undergoing pulmonary vein isolation </plain></SENT>
<SENT sid="4" pm="."><plain>In 10/430 (2.3 %), an LA <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> was found despite therapeutic OAC (mean INR 2.6 ± 0.6; range, 2.0-3.8) over the previous 4 weeks </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Two study groups were identified: 1 </plain></SENT>
<SENT sid="6" pm="."><plain>T-positive group = with LAA <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> (10 patients) 2 </plain></SENT>
<SENT sid="7" pm="."><plain>T-negative group = without LAA <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> (420 patients) The T-positive patients had a higher CHADS(2) score (1.5 ± 0.7 versus 0.7 ± 0.8; p = 0.004), a lower LVEF (54.7 ± 9.5 % versus 60.2 ± 7.4; p = 0.02), and a larger LA size (LA diameter, 56 ± 12.2 mm versus 46 ± 6.5 mm; p  &lt; 0.001and normalized LA volume: 140.2 ± 66 ml/m² vs. 67 ± 39 ml/m²; p &lt; 0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>On multivariate analysis, a larger LA diameter and normalized LA volume (OR, 1.14; 95 % C.I., 1.04-1.26; p = 0.006 and OR, 1.02; 95 % C.I., 1.01-1.03; p = 0.001, respectively) and a higher CHA(2)DS(2)VASc score (OR, 2.4; 95 % C.I., 1.4-4.2; p = 0.001) predicted left atrium appendage (LAA) <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>In another 42/430 (9.8 %) patients, an LA spontaneous echo-contrast (SEC) was detected </plain></SENT>
<SENT sid="10" pm="."><plain>Thus, cumulatively, 52/430 (12.1 %) patients had either LAA <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> (10 patients) or SEC (42 patients) </plain></SENT>
<SENT sid="11" pm="."><plain>LA diameter continued to predict the presence of either <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> or SEC (OR, 1.14; 95 % C.I., 1.07-1.2; p &lt; 0.05) </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: We found a 2.3 % prevalence of LA <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> (12.1 % when SEC was also considered) </plain></SENT>
<SENT sid="13" pm="."><plain>The <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> was present despite on-target <z:chebi fb="8" ids="10033">warfarin</z:chebi> prevention </plain></SENT>
<SENT sid="14" pm="."><plain>In addition to a higher CHA(2)DS(2)VASc score, a larger LA size was a strong predictor of clot detection </plain></SENT>
</text></document>